First report of cryptococcosis due to Cryptococcus gattii sensu stricto VGI in an Ivorian HIV negative patient

J Mycol Med. 2021 Jun;31(2):101113. doi: 10.1016/j.mycmed.2021.101113. Epub 2021 Jan 16.

Abstract

Introduction: Cryptococcus gattii species complex is endemic to tropical and subtropical regions and is described as a causative agent of cryptococcosis in immunocompetent individuals.

Case presentation: We describe the first case of cryptococcosis in a HIV-negative patient from Ivory Coast infected by Cryptococcus gattii sensu stricto VGI. Isolates were recovered from cerebrospinal fluid (CSF) prior to systemic antifungal treatment up to 42 days after detection of the presence of yeasts in the CSF. Eighteen isolates were recovered, genetic diversity and antifungal susceptibility analyses were performed. All the isolates belonged to the Cryptococcus gattii sensu stricto (B;VGI) and were identified as a new sequence type (ST) 553 by Multilocus Sequence Typing (MLST) analyses. Susceptibility testing showed that all the strains had a wild-type phenotype for fluconazole, amphotericin B and flucytosine. Treatment with fluconazole (1200mg/day) was initiated with success.

Conclusion: This is the first case report of the presence of C. gattii sensu stricto VGI in a HIV-negative ivorian patient and the second report of the presence of species from the C. gattii complex species in this country.

Keywords: Antifungal susceptibility testing; Cryptococcus gattii complex species; MLST; Non-HIV individual.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use
  • Cote d'Ivoire
  • Cryptococcosis / cerebrospinal fluid
  • Cryptococcosis / diagnosis*
  • Cryptococcosis / drug therapy
  • Cryptococcosis / microbiology
  • Cryptococcus gattii / classification
  • Cryptococcus gattii / drug effects*
  • Cryptococcus gattii / genetics*
  • Cryptococcus gattii / pathogenicity
  • Female
  • Genetic Variation
  • Genotype*
  • HIV Infections
  • Humans
  • Microbial Sensitivity Tests

Substances

  • Antifungal Agents